|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the clinicopathologic characteristics of the MFV-PTC treated in the Yonsei University College of Medicine.Between September 2007 and July 2012, 18,697 patients with PTC were treated in our institution.
|
29489673 |
2018 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer.
|
29657135 |
2018 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CCI = Charlson Comorbidity Index; CCR = California Cancer Registry; CI = confidence interval; DTC = differentiated thyroid cancer; FTC = follicular thyroid carcinoma; HCC = Hürthle cell carcinoma; IQR = interquartile range; mPTC = papillary thyroid micro-carcinoma; OR = odds ratio; OSPHD = Office of Statewide Health Planning and Development; PTC = papillary thyroid carcinoma.
|
28816539 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We found a significant association between the localization of RET mutations and the expression of three genes: NNAT (suggested to be a tumour suppressor gene), CDC14B (involved in cell cycle control) and NTRK3 (tyrosine receptor kinase that undergoes rearrangement in papillary thyroid cancer).
|
28181547 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Comparing the cytological or, when performed, histological diagnoses with the results of FNAB-Tg, we found that in 24 cases of lymph node metastases from PTC (19 lymph nodes from patients at the first diagnoses and 5 lymph nodes from PTC patients in follow up) the mean level of Thyroglobulin was 1840.11 ng/ml; range: <0,2 to 11440 ng/ml.
|
28558632 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
AACE = American Association of Clinical Endocrinologists EFVPTC = encapsulated FVPTC FNA = fine-needle aspiration FVPTC = follicular variant of papillary thyroid carcinoma NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features PTC = papillary thyroid carcinoma.
|
28920749 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Both phosphatases were studied in three PCCL3 rat thyroid cell lines that express doxycycline inducible PTC oncogenes (RET/PTC3, H-RASV12 or BRAFV600E).
|
28910386 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results showed an increasing trend of BRAF and a decreasing trend of RET/PTC prevalence over time in PTCs and classical PTCs, accompanied by an older age of PTC patients, an increase in proportion of PTMC and less aggressive behaviours of tumours.
|
27793009 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Twenty-nine (38.2%) of 76 <i>BRAF</i> and <i>RAS</i> wild-type classical PTCs had <i>RET/PTC1</i> rearrangement.
|
28417935 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We showed that RET is required for cell survival in medullary (MTC) but not papillary thyroid carcinoma (PTC) cells.
|
27872141 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although PTC-CCV may demonstrate features that overlap with those of the classic variant of PTC, hypercellular smears with papillary structures covered by cells with pseudostratified nuclei that show a paucity of nuclear pseudoinclusions and grooves should alert the cytopathologist to the possibility of this diagnosis.Cancer Cytopathol 2017;125:389-97.© 2017 American Cancer Society.
|
28374549 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Further, the significant increase of blunt-ended, double-stranded DNA breaks, but not other types of DNA breaks, in normal cells from patients with RET/PTC-driven tumors suggests that blunt-ended double-stranded DNA breaks are a preferred substrate for rearrangement formation, and implicate involvement of the non-homologous end joining pathway in the formation of RET/PTC rearrangements.
|
28069693 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MATERIAL AND METHODS Four cell lines included TPC-1 (BRAFWT/WT), BCPAP (BRAFV600E/V600E), PCCL3, and PTC3-5 (RET/PTC), were grown in culture in vitro with or without suppression of NF-κB using pyrrolidine dithiocarbamate (PDTC), and cell proliferation, and cell migration were evaluated.
|
29117154 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Certain mutations, such as mutations of BRAF in papillary thyroid carcinoma and mutations in RET codons 883, 918, and 928, are associated with an aggressive course in medullary thyroid carcinoma, and affected patients need close surveillance.
|
27618325 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results highlight an important role of <i>miR-195</i> in the initiation and progression of PTC and implicate the potential application of <i>miR-195</i> in PTC target therapy.
|
28740507 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Data regarding <i>RAS</i> mutations and <i>RET/PTC</i> fusions were insufficient for meta-analyses.
|
28219937 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Microscopic examination of CMV-PTC revealed predominately cribriform and morular pattern of cancer cells with characteristic nuclear features of papillary thyroid carcinoma.Psammoma body is rare.
|
28314770 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
|
28030816 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Discovering the mechanism of PTC genesis and progression and finding new potential diagnostic biomarkers/therapeutic target genes of PTC are of great significance.
|
28673327 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Small papillary thyroid cancer (PTC) generally has an excellent prognosis.
|
27732329 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FNA = fine-needle aspiration miRNA = micro RNA NGS = next-generation sequencing NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features NPV = negative predictive value PPV = positive predictive value PTC = papillary thyroid carcinoma RAI = radioactive iodine.
|
28534687 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thyroid tissue blocks from 42 consecutive pediatric WDTC patients who underwent thyroidectomy between 2001 and 2013 were analyzed at Quest Diagnostics for BRAF(V600E), RAS mutations (N,K,H), and RET/PTC and PAX8/PPARγ rearrangements, using validated molecular methods.
|
26649796 |
2016 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
XRCC1 T-77C polymorphism affects the genetic susceptibility for PTC development in men, the specific combination of XRCC1 haplotypes correlates with RET/PTC incidence, CDKN1B Val109Gly significantly influences the risk of developing PTC regardless of gender and in PTC cases, selected genotypes of TP53 Arg72Pro and ATM Asp1853Asn were significantly associated with monitored tumour characteristics.
|
27314298 |
2016 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this Review, we discuss the pathogenic, diagnostic and prognostic roles of the RET proto-oncogene in both PTC and MTC.
|
26868437 |
2016 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Six of 27 PTCs (22%) had ret proto-oncogene (RET) fusions (RET/PTC1, n = 5; RET/PTC3, n = 1); 2 tumors measured >2 cm and diffusely involved the thyroid, and 5 had lymphatic invasion, with vascular invasion in 2.
|
26784937 |
2016 |